Pendium

Step 1 of 9

Thorne owns the clinical supplement conversation, but newer longevity tech players are chipping at the edges.

The brand is a foundational recommendation for vitamins and minerals; the next battle is winning the highly specific 'biological age' and 'personalized stack' queries.

Thorne's baseline score
82/100
Excellent

Thorne exhibits dominant AI visibility, scoring in the top tier of its category due to massive editorial and professional authority. While it remains a default recommendation for purity-seeking buyers, emerging competition in personalized longevity tech creates a strategic opening for competitors.

What we see
  • Thorne maintains dominant visibility for 'NSF Certified for Sport' and 'professional-grade multivitamin' queries across all platforms.
  • Claude and ChatGPT show a strong preference for Thorne over Pure Encapsulations in head-to-head quality comparisons.
  • There is a notable visibility gap in 'biological age testing' and 'longevity tech' queries where Thorne is often out-named by newer, tech-first players like Elysium or InsideTracker.
  • Gemini's sentiment is slightly more volatile due to the inclusion of high volumes of Reddit commentary discussing the 2023 acquisition.
Business goals Thorne is likely trying to hit
  • Deepen market share within the Gen Z and Millennial biohacking demographic
  • Establish Taia as the industry-standard AI health advisor to drive high-margin repeat sales
  • Maintain premium brand equity following the L Catterton acquisition
  • Expand the adoption of at-home biological testing as a funnel for supplement subscriptions